Outcome of the Board of Directors Meeting held on Friday, May 29, 2026
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences reported FY2026 standalone revenue of Rs. 9,404.66 Lakhs, up 14.7% from Rs. 8,198.06 Lakhs in FY2025. However, net profit declined 9.7% to Rs. 6,314.87 Lakhs from Rs. 6,993.28 Lakhs, primarily due to increased finance costs (Rs. 3,661.14 Lakhs vs Rs. 2,311.16 Lakhs) and higher tax expenses. EBITDA margin compression is evident as total expenses grew faster than revenue. The Board recommended a 10% dividend (Rs. 0.10 per share) and approved Rs. 5.75 Crore investment in Saraswat Co-operative Bank Limited. Statutory auditors issued an unmodified (clean) opinion on the financial statements. Current borrowings increased significantly to Rs. 28,012.69 Lakhs from Rs. 17,987.50 Lakhs last year, while inventories rose sharply to Rs. 32,446.66 Lakhs from Rs. 21,686.90 Lakhs.
Revenue growth of 14.7% is positive but PAT decline of 9.7% and rising borrowings may concern investors. The clean audit opinion provides assurance. Dividend and banking investment are neutral to mildly positive.